埃迪鲁单抗
| 单克隆抗体 | |
|---|---|
| 种类 | 完整抗体 |
| 目标 | CXCL10 |
| 临床资料 | |
| ATC码 |
|
| 识别信息 | |
| CAS号 | 946414-98-8 |
| ChemSpider |
|
| UNII | |
| KEGG | |
| 化学信息 | |
| 化学式 | C6502H10024N1736O2026S48 |
| 摩尔质量 | 146,468.72 g·mol−1 |
埃迪鲁单抗（INN：eldelumab；开发代号：BMS-936557[1]）或译依德鲁单抗，是一种抗CXCL10全人单克隆抗体（IgG1 κ型）[2][1]，设计用于治疗克罗恩病和溃疡性结肠炎。[3]
参考资料
[编辑]- ^ 1.0 1.1 Sandborn WJ, Colombel JF, Ghosh S, Sands BE, Dryden G, Hébuterne X, et al. Eldelumab [Anti-IP-10] Induction Therapy for Ulcerative Colitis: A Randomised, Placebo-Controlled, Phase 2b Study. Journal of Crohn's & Colitis. April 2016, 10 (4): 418–28. PMC 4946756
. PMID 26721935. doi:10.1093/ecco-jcc/jjv224.
- ^ Anti-CXCL10 Therapeutic Antibody (eldelumab) - Creative Biolabs. www.creativebiolabs.net. [2017-03-24]. （原始内容存档于2024-05-25）.
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Eldelumab （页面存档备份，存于互联网档案馆）, American Medical Association.
- ^ Eldelumab. AdisInsight. Springer Nature Switzerland AG. [2024-05-25]. （原始内容存档于2017-11-05）.
